USPTO serial 99675535
BELLEDO
Reviewed by CopyMark Law Group
Status 653
- Filing date
- Status date
- Registration date
- —
- Examiner
- GIPSOV, MARYNA K
- Law office
- TMO LAW OFFICE 127
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with BELLEDO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Cheongju-si, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kiranjit K Dharsan
Kiranjit K Dharsan Seiter IP1110 N Virgil Ave, Suite #98436Los Angeles, CA 90029United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Muscle relaxants; Pharmaceutical agents affecting peripheral nervous system; Pharmaceuticals containing botulinum toxin, namely, botulinum toxin for medical use in the treatment of glabellar lines, forehead wrinkles, lateral canthal lines, migraine headache, overactive bladder, urge incontinence, prostate disorder, cervical dystonia, spasticity, muscle dystonia, blepharospasm, hyperhidrosis, strabismus, neuropathy pain, excessive sweating, excessive eye blinking, facial wrinkles and pelvic pain; Bacteria poisons; Pharmacological preparations for skin care; Chemical pharmaceutical preparations, namely, for the treatment of neurological disorders, muscle dystonia, spasticity, chronic migraine, hyperhidrosis, dermatological conditions, and facial wrinkles; Biological preparations for use in cell cultures for medical or veterinary purposes; Pharmaceutical syringes sold prefilled with medical botulinum toxin as the main ingredient; Implantable medicines being injectable dermal fillers; Pharmaceutical preparations acting on the central nervous system; Pain relief medication; Injectable anti-aging preparation, namely, injectable botulinum toxin formulations for cosmetic use and wrinkle reduction | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 15, 2026 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Sep 15, 2026 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Sep 15, 2026 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Sep 14, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 14, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 14, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 15, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 15, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 28, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 28, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 28, 2026 | NWAP | NEW APPLICATION ENTERED | — |